BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 8520180)

  • 1. Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.
    Schmidt-Sarosi C; Kaplan DR; Sarosi P; Essig MN; Licciardi FL; Keltz M; Levitz M
    J Assist Reprod Genet; 1995 Mar; 12(3):167-74. PubMed ID: 8520180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The luteal phase after ovulation induction with human menopausal gonadotropin and one versus two doses of a gonadotropin-releasing hormone agonist.
    Corson SL; Batzer FR; Gocial B; Maislin G
    Fertil Steril; 1993 Jun; 59(6):1251-6. PubMed ID: 8495774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of leuprolide acetate and human chorionic gonadotropin for the induction of ovulation in clomiphene citrate-stimulated cycles.
    Scott RT; Bailey SA; Kost ER; Neal GS; Hofmann GE; Illions EH
    Fertil Steril; 1994 May; 61(5):872-9. PubMed ID: 8174724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Fertil Steril; 2002 Apr; 77(4):733-7. PubMed ID: 11937125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
    Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
    Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
    Fraser HM; Nestor JJ; Vickery BH
    Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotrophin-releasing hormone agonist compared with human chorionic gonadotrophin for ovulation induction after clomiphene citrate treatment.
    Shalev E; Geslevich Y; Matilsky M; Ben-Ami M
    Hum Reprod; 1995 Oct; 10(10):2541-4. PubMed ID: 8567766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous LH surge versus hCG as ovulation trigger after low-dose highly purified FSH in IUI: a comparison of 761 cycles.
    Romeu A; Monzó A; Peiró T; Diez E; Peinado JA; Quintero LA
    J Assist Reprod Genet; 1997 Oct; 14(9):518-24. PubMed ID: 9401870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of different protocols of ovulation induction, by GnRH agonists and chorionic gonadotropin].
    Parneix I; Emperaire JC; Ruffie A; Parneix P
    Gynecol Obstet Fertil; 2001 Feb; 29(2):100-105. PubMed ID: 11262842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin).
    Schriock ED; Monroe SE; Martin MC; Henzl MR; Jaffe RB
    Fertil Steril; 1985 Jun; 43(6):844-50. PubMed ID: 3158549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine modifications associated with final oocyte maturation with gonadotropin-releasing hormone agonists vs. human chorionic gonadotropin in women undergoing intrauterine insemination.
    Díaz I; Guillén A; Pacheco A; Requena A; Garcia-Velasco JA
    J Reprod Med; 2008 Jan; 53(1):33-9. PubMed ID: 18251359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desensitization of both luteal and pituitary function in baboons with nafarelin, a potent LH-RH agonist.
    Vickery BH; Powell J; Stevens VC
    Int J Fertil; 1988; 33(3):188-93. PubMed ID: 2899565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial.
    Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H
    Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.